Jim Oates to Immunologic Factors
This is a "connection" page, showing publications Jim Oates has written about Immunologic Factors.
Connection Strength
0.151
-
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan; 62(1):222-33.
Score: 0.079
-
Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol. 2008 Aug; 42(7):862-3.
Score: 0.072